Version 1
: Received: 11 November 2020 / Approved: 12 November 2020 / Online: 12 November 2020 (10:28:50 CET)
How to cite:
Thongchandee, O.; Khatab, K.; Raheem, M. Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints2020, 2020110341. https://doi.org/10.20944/preprints202011.0341.v1
Thongchandee, O.; Khatab, K.; Raheem, M. Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints 2020, 2020110341. https://doi.org/10.20944/preprints202011.0341.v1
Thongchandee, O.; Khatab, K.; Raheem, M. Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints2020, 2020110341. https://doi.org/10.20944/preprints202011.0341.v1
APA Style
Thongchandee, O., Khatab, K., & Raheem, M. (2020). Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints. https://doi.org/10.20944/preprints202011.0341.v1
Chicago/Turabian Style
Thongchandee, O., Khaled Khatab and Maruf Raheem. 2020 "Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand" Preprints. https://doi.org/10.20944/preprints202011.0341.v1
Abstract
Aim: This research is aimed at examining the cost-effectiveness of olanzapine versus risperidone in dementia patients with behavioural and psychological symptoms in Thailand. Methods: An existing Markov model based on a critical review through the comprehensive literature search and a justification for the most appropriate model for a Thai setting was adapted to simulate the disease progression of patients with dementia with behavioural disturbances until their need for full-time care (FTC). The time to the FTC state was estimated by a predictive equation developed by Rive et al. (2010). The model was conducted to assess the expected costs and outcomes associated with olanzapine compared with risperidone for Thai patients with BPSD aged 60 years and above. This model performed over a five-year time horizon with a one-month cycle length based on a societal perspective. The incremental cost-effectiveness ratio was used as the estimated outcome. Sensitivity analyses were also conducted to demonstrate the robustness of the results. Results: Over 5 years, olanzapine was found to be a cost-effective therapeutic option for the treatment of behaviourally disturbed patients with dementia compared with risperidone, in Thailand from a societal perspective (ICER < THB 160,000). The model underwent extensive sensitivity analyses, which also confirmed that olanzapine was the dominant strategy following the base-case findings. Conclusions: By comparison with risperidone, the model suggests that olanzapine can be regarded as a cost-effective therapeutic strategy for the management of patients with behavioural and psychological symptoms in Thailand.
Business, Economics and Management, Accounting and Taxation
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
